Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis

W. Taylor Kimberly, John F. O’Sullivan, Anjali K. Nath, Michelle Keyes, Xu Shi, Martin G. Larson, Qiong Yang, Michelle T. Long, Ramachandran Vasan, Randall T. Peterson, Thomas J. Wang, Kathleen E. Corey, Robert E. Gerszten

Resultado de la investigación: Articlerevisión exhaustiva

43 Citas (Scopus)


The discovery of metabolite-phenotype associations may highlight candidate biomarkers and metabolic pathways altered in disease states. We sought to identify novel metabolites associated with obesity and one of its major complications, nonalcoholic fatty liver disease (NAFLD), using a liquid chromatography–tandem mass spectrometry method. In 997 individual in Framingham Heart Study Generation 3 (FHS Gen 3), we identified an association between anandamide (AEA) and BMI. Further examination revealed that AEA was associated with radiographic hepatic steatosis. In a histologically defined NAFLD cohort, AEA was associated with NAFLD severity, the presence of nonalcoholic steatohepatitis, and fibrosis. These data highlight AEA as a marker linking cardiometabolic disease and NAFLD severity.

Idioma originalEnglish (US)
Número de artículoe92989
PublicaciónJCI Insight
EstadoPublished - may. 4 2017
Publicado de forma externa

ASJC Scopus subject areas

  • Medicine(all)


Profundice en los temas de investigación de 'Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis'. En conjunto forman una huella única.

Citar esto